Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Prescription Drug

Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying'

Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative “a good start,” while still acknowledging its limitations.

Benzinga

TrumpRx.Gov vs. Mark Cuban’s Cost Plus Drugs: Which Saves Retirees More?

Billionaire celebrity Mark Cuban disrupted the prescription drug industry when he launched the digital pharmaceutical marketplace CostPlus Drugs in 2022. President Donald Trump recently announced a...

GOBankingRates

Sunshine Biopharma Stock Is Surging Thursday: Here's What's Happening

Shares of Sunshine Biopharma Inc. (NASDAQ:SBFM) are trading higher Thursday after the Florida-based pharmaceutical company announced the launch of a generic prescription drug.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Medicare Open Enrollment: Why You Need to Pay Extra Attention to Part D, From a Financial Adviser

The lowest premium for prescription drug coverage might not actually save you the most money. Make sure you take copays into consideration and do the math.

Kiplinger

3 Biggest Changes to Medicare That Took Place in 2025 — How To Plan For 2026

Medicare changed again in 2025 -- affecting premiums, prescription drug costs and how you pay for medications. Make a plan now for your 2026 Medicare.

GOBankingRates

Trump's Rx for confusion: How a push for tariffs complicated his pharma plan

The president's road to settling on a plan to lower prescription drug costs was rocky.

Axios

Prescription drug coverage options are shrinking for Medicare shoppers

Fewer choices may be on the menu again as Medicare patients shop for prescription coverage this fall

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans

President Donald Trump is reportedly set to announce a new agreement with AstraZeneca Plc (NASDAQ:AZN) designed to reduce prescription drug costs for Americans.

Benzinga

Miss One Drug Refill and Face Lifetime Penalty—What to Know

Medicare offers prescription drug coverage through Part D, but the rules behind it can feel like a trap. Many seniors don’t realize that missing just...

Saving Advice

Major Insurers Scale Back Medicare Advantage and Part D Plans for 2026

Beneficiaries enrolled in Medicare Advantage and Part D prescription drug plans might be losing their plan as UnitedHealthcare, Humana, and Aetna (CVS Health) scale back offerings for 2026.

Kiplinger

Moderna Stock Is Rallying Wednesday: What's Driving The Action?

Moderna Inc (NASDAQ:MRNA) stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector. The rally follows a landmark agreement Tuesday between Pfizer Inc (NYSE:PFE) and the Trump administration to lower prescription drug prices.

Benzinga

Pfizer agrees to lower prescription drug costs for Medicaid

Under the deal, New York-based Pfizer will charge most-favoured-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations.

Euronews

Medicare Beneficiaries To See Slight Premium Decline Next Year

The Centers for Medicare Medicaid Services (CMS) announced on Friday that Medicare Advantage (MA) and Medicare Part D prescription drug program premiums, benefits and plan options are expected to remain largely stable in 2026.

Benzinga

Medicare Part D Caps You Didn’t Know Existed Until Now

Most Medicare users know about deductibles and copays, but fewer realize that Part D prescription drug plans come with several hidden caps that can quietly...

Saving Advice

Get all your
news in one place.

100's of premium titles.
One news app.

GOBankingRates

Will Trump’s Tariffs Spike Your Cost for Prescription Meds? Experts Weigh In

How will Trump's tariffs impact prescription drugs in the U.S.? Let's find out.

Saving Advice

Medicare Reforms That Limit Prescription Costs—But Still Leave Gaps You’ll Pay For

For years, prescription drug costs have been one of the biggest financial burdens for seniors. Medicare reforms rolling out in 2025 aim to fix part...

Saving Advice

9 Part D Shopping Tricks That Cut Annual Costs

Prescription drug costs weigh heavily on retirees’ budgets. Medicare Part D offers relief, but choosing the wrong plan can waste hundreds—or even thousands—each year. The...

Saving Advice

8 Medicare Part D Decisions That Change Your Annual Drug Costs Drastically

Prescription drug costs remain one of the biggest worries for retirees. Medicare Part D was designed to help, but the program is full of choices...

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

RFK Jr.'s latest 'Make America Healthy Again' report calls for more scrutiny of vaccines and autism

The Trump administration is urging public health agencies to prioritize investigations of vaccine injuries, prescription drug use, and the cause of autism

Benzinga

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing

Billionaire entrepreneur Mark Cuban, in a series of posts on the social media platform X early Monday morning, launched a scathing critique of the U.S. prescription drug industry, accusing large wholesalers and Pharmacy Benefit Managers (PBMs) of creating a “stranglehold” on pricing through opaque, anti-competitive practices.

Benzinga

FDA Delays Decision On Agios Pharmaceuticals' Blood Disorder Drug For Expanded Use

On Thursday, the U.S. Food and Drug Administration (FDA) extended the Prescription Drug User Fee Act (PDUFA) goal date for Agios Pharmaceuticals, Inc.’s (NASDAQ:AGIO) supplemental New Drug Application (sNDA) of Pyrukynd (mitapivat) for adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.

Benzinga

FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months

The U.S. Food and Drug Administration (FDA) on Monday extended the Prescription Drug User Fee Act (PDUFA) goal date for Axogen Inc.’s (NASDAQ:AXGN) Biologics License Application (BLA) for Avance Nerve Graft by three months to December 5.

The Free Financial Advisor

Want to Delay Part D Prescriptions Over Time Instead of Paying Upfront? It Begins Jan 1

High prescription drug costs are one of the biggest burdens retirees face, but a new option is set to bring relief. If you want to delay Part D prescriptions and spread payments out over time instead of paying them all upfront, a change beginning Jan 1 makes it possible. This…

The Free Financial Advisor

Retirees Face $172,500 in Healthcare Costs—And Many Haven’t Saved for It

For many people, retirement planning focuses on housing, leisure, and day-to-day living expenses. But there’s one major cost that catches many off guard — healthcare. Recent estimates show that retirees face $172,500 in healthcare costs—and many haven’t saved for it. That figure covers expenses like Medicare premiums, prescription drugs, and…

Budget and the Bees

8 Costs Retirees Can Stop Paying Today Thanks to New Medicare Changes

Retirement should be a time to enjoy the fruits of your labor. However, for many, managing a fixed income can be a significant source of stress. Healthcare often becomes one of the largest and most unpredictable expenses. Specifically, prescription drug costs pose a particular challenge. Fortunately, recent legislative updates are…

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.